Another great post by JFM to a

New Post Public Reply Private Reply Replies (1) Message Board
Rip Van 03
666
Another great post by JFM to a basher:

XXXXXXXXXX...

Your attempt to discredit another post, which noted:

Brilacidin via RBL's “... has proven to be over 90 percent effective in destroying Covid-19 AND its variants in lab results”

by asserting:

"Incorporating such obvious “inaccuracies “ into your communications will diminish their impact considerably"

...is like spitting in the wind!

I AGREE...that INCORPORATING SUCH OBVIOUS INACCURACIES...DIMINISH COMMUNICATIONS IMPACT...AS WITH YOURS!!!

But...by also posting:

"Once again your statement that brilacidin has been shown to be effective against variant COVID-19 strains is flat out false."


...is in itself...FLAT OUT FALSE.

Tyrus603...was obviously using "effective" as meaning the REDUCTION IN COVID-19 VIRAL LOAD, using human tissue, as much as 97% as reported by RBL after extensive testing ... ...

WHICH IS ABSOLUTELY CORRECT...

...unless of course you are implying that we are to believe that what Rutgers Univ. and GMU Univ. reported...i.e. the REDUCTIONS IN VIRAL LOADS up to 97% in their labs...was some kind of co-conspiracy by the Labs...with Leo/CEO in publishing the PR below...

...and that they together fooled the FDA accepting those (your) "alleged inaccuracies" resulting in the...

FDA GRANTING ..."INVESTIGATIONAL NEW DRUG" approval AND "FAST TRACT DESIGNATION"...just last month!

YES...“inaccuracies “ into your communications will diminish their impact considerably"!!!

Read PRESS RELEASE SUMMARIZING ... INDEPENDENT GOV SPONSORED lab results for Brilacidin:

http://www.ipharminc.com/press-release/2020/6...-cell-line

· "Brilacidin is a unique 3-in-1 antiviral, anti-inflammatory, antimicrobial COVID-19 drug candidate..."

"Brilacidin exhibited a statistically significant (p<0.0001) and potent inhibitory effect on SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human lung epithelial cell line—reducing viral load by 95 percent and by 97 percent, compared to control, at two therapeutic concentrations tested. Based on a CC50 value—the concentration of drug at which 50 percent of cells maintain viability—Brilacidin was also shown to be non-cytotoxic in the lung cell line.

The new lung cell line data reinforce previous testing conducted at the RBL, in VERO cells, where Brilacidin showed a similar robust inhibition, of 75 percent, against SARS-CoV-2 compared to control. Brilacidin has also been shown, in testing at the RBL, to be non-cytotoxic in VERO cells."


“Brilacidin has now demonstrated potent inhibition of SARS-CoV-2 in human lung and kidney cell lines, and in VERO cells, in laboratory testing conducted by independent academic researchers at two institutions, both of whom plan to submit their findings for peer-review publication,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “The antiviral data we are compiling provides compelling proof of Brilacidin’s impressive ability to inhibit the novel coronavirus, toward initiating a clinical study of Brilacidin for COVID-19.”

PS. Those clinical trials...are EXPECTED TO BE INITIATED THIS WEEK...to prove out the lab results in humans!

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

How Track Rabbit Levels the Playing Field for Small Motorsport Ventures

Updated Category News Views 3

Fielding Opportunities in a Revved-Up Market You're knee-deep in grease and exhaust, keeping your motorsport enterprise alive against the big dogs without losing grip on the little guy's budget. What if I told you there's a service out there talking your language – combining marketing prowess with AI smarts for as low as $350 a month? That's ALIVE and Track Rabbit...

Continue Reading
Former OB/GYN Faces $9M Verdict After Negligence Trial

Updated Category News Views 5

A Tragic Verdict Worth Millions In the heart-wrenching case of former OB/GYN Arthur Park, the verdict has fallen like a ton of bricks. A jury in Bakersfield, California, has determined that Park's negligent care led to fatalities, resulting in a mammoth $9.25 million payout to two grief-stricken families. It's a bitter pill to swallow for Arthur Park, but an expected...

Continue Reading
Top Seedz: Seeds Drive Growth in Crowded Cracker Market

Updated Category News Views 2

Breaking the Cracker Mold with Seeds Ever thought crackers could be more than just a canvas for cheese? Well, Top Seedz out of Buffalo is redefining the snack aisle with its seed-centric approach. In a whopping $25 billion global cracker market, this woman-owned outfit is carving out its niche by flipping conventional recipes on their heads. They're not just tossing seeds...

Continue Reading
Labcorp Scoops Up BioReference Health For $722M+

Updated Category News Views 7

Picture this: You’re a big fish like Labcorp ready to feast on smaller catches. That’s exactly what’s rolling out as OPKO Health cuts a deal to offload a chunk of its BioReference Health assets to Labcorp for a tidy $722 million in cash. Assets on the Move OPKO’s BioReference Health has long been a player in the clinical testing world, with a focus on services...

Continue Reading
Duolingo Faces Class Action: Investors Brace for Impact

Updated Category News Views 4

Going Beyond Language Learning Hype Listen, it's not every day you wake up to a lawsuit calling out one of those seemingly indestructible tech darlings. Well, Duolingo (NASDAQ: DUOL) is caught in the crosshairs now. They face allegations of pulling the wool over investors' eyes about their monetization and growth tactics. If you snapped up some stock between May 2, 2025,...

Continue Reading
Sony's Game-Changing Sensor Reshapes Medical Endoscopy

Updated Category News Views 3

In a world where medical tech innovation can make the difference between life and death, Sony’s latest feat will turn some heads in the healthcare industry. This ain’t about another PlayStation release; we’re talking the IMX742 CMOS image sensor crafted for single-use endoscopes. As far as breakthroughs go, the microscopic square sensor packs a surprising punch by...

Continue Reading
Amcor's Q3 2026 Results Loom: What's at Stake?

Updated Category News Views 3

Anticipation Builds for Amcor's Q3 2026 Financials Well, here we are again, staring down the barrel of another quarterly earnings report from Amcor plc (NYSE: AMCR). They've circled November 4th, 2026, in red on their calendars to dish out the numbers after the U.S. market's last bell rings. Investors, analysts, and the peanut gallery will be tuning in, and why not? At a...

Continue Reading
ILS and Anduin Join Forces to Streamline Fundraising

Updated Category News Views 1

Big Moves in Legal Tech and Fundraising In the world of investing, where technology is always a step ahead, Intelligent Legal Solutions (ILS) and Anduin are cooking up a storm with their latest partnership announcement. Targeting private markets fund managers and law firms, these two tech players aim to ease the layered chaos that comes with fundraising by integrating...

Continue Reading
India's Bharat RE 2026 Amidst Global Energy Stakes

Updated Category News Views 5

India's Ambitious Energy Vision Diving right into it, India's ready to slap its mighty stamp on the global clean energy landscape. This grand affair, Bharat Renewable Energy Summit & Expo 2026, is calling in the big wigs from over 130 countries to New Delhi. It's not a casual gathering either—it's a serious play to crank up investment and tech alliances in renewable...

Continue Reading
Epson's Robotics Innovation Takes Center Stage at ASSEMBLY

Updated Category News Views 7

No More Robots in the Background Walking into The ASSEMBLY Show 2026, you'd think robots had finally emerged from their hushed backstage roles and are now ready to claim their rightful place in the spotlight. Epson's leading the charge with their fresh AX6 collaborative robot, a machine that might just change the game for good. AX6 Cobot: The New Kid on the Block Epson's...

Continue Reading

Top 5 Most Recently Viewed Articles

Raising Awareness for Skin Cancer: The #WearSunscreen Initiative

Updated Category News Views 374

Raising Awareness for Skin Cancer: The #WearSunscreen Initiative On World Health Day, the Personal Care Products Council (PCPC) proudly launched the impactful #WearSunscreen campaign. This nationwide initiative aims to motivate people to incorporate sunscreen into their daily routines, emphasizing its importance in skin protection. Surprisingly, while over half of...

Continue Reading
Azitra Partners with Alumni Capital for Funding Clinical Projects

Updated Category News Views 207

Azitra Forms Strategic Alliance with Alumni Capital Azitra, Inc. (NYSE American: AZTR), a pioneering clinical stage biopharmaceutical company, has taken a significant step to bolster its clinical pipeline. In a recent announcement, Azitra declared that it has established a share purchase agreement (SPA) with Alumni Capital LP, an institutional investor. This partnership...

Continue Reading
Global Leaders Unite to Drive Sustainable Finance Forward

Updated Category News Views 203

Global Leaders Unite to Drive Sustainable Finance Forward The United Nations Global Compact (UNGC) and Principles for Responsible Investment (PRI) held a significant event focusing on sustainable finance. This meeting, dubbed the Executive Roundtable on Sustainable Finance – Driving Leadership in Sustainable Finance for a Resilient Future, took place at a luxury hotel...

Continue Reading
EEW Renewables and Compass Digital Merge for Growth in Renewables

Updated Category News Views 85

EEW Renewables Partners with Compass Digital Acquisition Corp. EEW Renewables Ltd, a leader in the renewable energy industry, is making significant progress with its recent partnership with Compass Digital Acquisition Corp. (Nasdaq: CDAQ). This collaboration marks an important shift in the renewable energy sector, aiming to amplify their combined efforts in sustainable...

Continue Reading
Goldman Sachs Top Stock Picks for 2025: Insights Revealed

Updated Category News Views 2640

Goldman Sachs Insights for Investors in 2025 As we look ahead to 2025, many of the leading investment banks and brokers are releasing their market predictions. These insights are important benchmarks for both institutional and retail investors. Goldman Sachs, in its recent macro outlook report, predicts significant rotations within various industry sectors, highlighting...

Continue Reading